Circadian rhythmicity and the pharmacologic management of insomnia

American Journal of Managed Care

Volumn 13, Issue 11 SUPPL. 5, 2007, Pages

  Richardson, Gary S ^b   Mitrzyk, Beatriz Manzor ^b   Bramley, Thomas J ^a  

^a XCENDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR STIMULATING AGENT; ESZOPICLONE; MELATONIN; MELATONIN RECEPTOR; RAMELTEON; TEMAZEPAM; TRIAZOLAM; ZOLPIDEM;

ADVANCED SLEEP PHASE SYNDROME; AMNESIA; ARTICLE; ATAXIA; BEDTIME DOSAGE; CIRCADIAN RHYTHM; CLINICAL STUDY; CONTROLLED DRUG RELEASE; DRUG APPROVAL; DRUG COST; DRUG SAFETY; HUMAN; INSOMNIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHIFT WORKER; SLEEP DISORDER; SLEEP WAKING CYCLE; UNSPECIFIED SIDE EFFECT;

CHRONOTHERAPY; COST-BENEFIT ANALYSIS; HUMANS; HYPNOTICS AND SEDATIVES; MANAGED CARE PROGRAMS; MELATONIN; RECEPTORS, MELATONIN; SLEEP DISORDERS, CIRCADIAN RHYTHM;

EID: 36849027663     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Winkelman J, Pies R. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry. 2005;17:31-40.
2. Léger D, Guilleminault C, Bader G, Levy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep. 2002;25:625-629.
3. Walsh JK. Insights into the public health burden of insomnia. Sleep. 2006;29:142-143.
4. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2005;22:1-30.
5. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev. 2004;8:63-72.
6. Godet-Cayré V, Pelletier-Fleury N, Le Vaillant M, Dinet J, Massuel MA, Léger D. Insomnia and absenteeism at work. Who pays the cost? Sleep. 2006;29:179-184.
7. Richardson GS. The human circadian system in normal and disordered sleep. J Clin Psychiatry. 2005;66(suppl 9):3-9.
8. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol. 2004;73:379-396.
9. Arendt J. Melatonin and human rhythms. Chronobiol Int. 2006;23:21-37.
10. Cassone VM. Effects of melatonin on vertebrate circadian systems. Trends Neurosci. 1990;13:457-464.
11. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-195.
12. Weitzman ED, Czeisler CA, Coleman RM, et al. Delayed sleep phase syndrome. A chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry. 1981;38:737-746.
13. Richardson GS. Shift work sleep disorder. Sleep: A Comprehensive Handbook. Lee-Chiong T, ed. Hoboken, NJ: John Wiley & Sons, lnc; 2006:395-399.
14. Knauth P, Rutenfranz J. Experimental shift work studies of permanent night and rapidly rotating shift systems. I. Circadian rhythm of body temperature and re-entrainment at shift change. Int Arch Occup Environ Health. 1976;37:125-137.
15. Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19:116-122.
16. Lack LC, Mercer JD, Wright H. Circadian rhythms of early morning awakening insomniacs. J Sleep Res. 1996;5:211-219.
17. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17-24.
18. Roth T, Seiden D, WangWeigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005-1014.
19. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495-504.
20. Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther. 2006;28:1540-1555.
21. Dündar Y, Boland A, Strobl J, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8:iii-x, 1-125.
22. Evaluating newer sedative drugs used to treat: insomnia. Comparing effectiveness, safety, and price. Consumer Reports Best Buy Drugs. August 2006.
23. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28:303-307.
24. Carson S, Yen PY, McDonagh MS. Drug class review on newer drugs for insomnia. Final report. July 2006. http://www.ohsu.edu/drugeffectiveness/ reports/final.cfm. Accessed June 25, 2007.
25. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63:1149-1157.